Madopar (Benserazide HCl/Levodopa) by Roche is the treatment for Parkinson's syndrome, and the generic was approved in Korea. Myungin, which is drawing attention in related markets for Perkin and Trilevo, is expected to expand its sales with the joining of generic for Madopar .

The MFDS approved Myungdopar by Myungin on the 14th. Myungdopar is a drug used in Parkinson's syndrome that is generic for Roche's Madopar. It is the first generic to be introduced in Korea. After receiving approval for the first biological equivalence test plan in May 2019, Myungin began developing generic for Madopar .

A single oral administration of Myungdopar to healthy adults was conducted to measure Levodop